A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/26/2011	CN101647790B Application of triacontanol for preparing anti-cancer medicine
10/26/2011	CN101638440B Heterogenetic antigen-Fc fusion protein capable of inducing antitumor immunity of organism and application thereof
10/26/2011	CN101618172B Traditional Chinese medicine for treating hepatitis B, cirrhosis, liver cancer and liver ascites
10/26/2011	CN101585880B Variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies
10/26/2011	CN101585863B Method for preparing yamogenin
10/26/2011	CN101525598B Method for purifying human urinary trypsin inhibitor
10/26/2011	CN101507740B Lysimachia capillipes Hemsl. total saponin extract preparation method using macroporous resin and use thereof
10/26/2011	CN101486772B Mistletoe polysaccharide, as well as preparation and use thereof
10/26/2011	CN101486726B Coupling agent for preparing radiotherapy marker, 211At marker prepared thereby and preparation
10/26/2011	CN101450214B Transferrin-frog-egg ribonuclease coupler and production method and use thereof
10/26/2011	CN101411739B Method for preparing Caesalpinia sappan water extract
10/26/2011	CN101386596B 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
10/26/2011	CN101348511B Synthesis and refinement of nelarabine
10/26/2011	CN101234113B Anti-tumor small molecular compound targeting to phosphatidylethanolamine conjugated protein 4 of human
10/26/2011	CN101218238B Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
10/26/2011	CN101088520B Medicine composition for auxiliary treatment of cancer and its prepn and quality control method
10/26/2011	CN101084980B Medicinal composition freezing-dried powder injection for cancer auxiliary treatment and its preparation method
10/26/2011	CN101063112B Nucleoside diphosphokinase A oxidation-reduction isomer
10/25/2011	US8044200 Enhance immunology response; ion exchanging with chromatography support
10/25/2011	US8044183 Process for the production of immunogenic compositions
10/25/2011	US8044182 Adiponectin and uses thereof
10/25/2011	US8044081 Aminoderivative of biotin and their conjugates with macrocyclic chelating agents
10/25/2011	US8044062 Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
10/25/2011	US8044049 Fused heterocyclic derivative and use thereof
10/25/2011	US8044040 e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis
10/25/2011	US8044037 Modified phosphocalcic compound, injectable composition containing same
10/25/2011	US8044018 Reagents and methods for smooth muscle therapies
10/25/2011	US8043831 Therapeutic agents comprising pro-apoptotic proteins
10/25/2011	US8043806 Method of diagnosing an RTK-hyperfunction induced disorder
10/25/2011	US8043623 Immunogenic peptides for the treatment of prostate and breast cancer
10/25/2011	US8043612 Infection and treatment of neoplasms with vesicular stomatitis virus
10/25/2011	CA2580910C Pharmaceutical composition comprising temozolomide ester
10/25/2011	CA2531862C Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
10/25/2011	CA2460834C Matrix metalloproteinase inhibitor
10/25/2011	CA2437983C Transporters comprising spaced arginine moieties
10/25/2011	CA2415923C Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
10/21/2011	CA2796624A1 Method of treating hepatocellular carcinoma
10/20/2011	WO2011130753A2 Functionalized nano- and micro-materials for medical therapies
10/20/2011	WO2011130749A2 Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
10/20/2011	WO2011130728A1 Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
10/20/2011	WO2011130692A2 Androgen induced oxidative stress inhibitors
10/20/2011	WO2011130677A1 Inhibitors of cancer stem cells
10/20/2011	WO2011130658A1 Custom designed microbubble contrast agents and techniques of ultrasound delivery optimized for nucleic acid delivery to alter gene expression
10/20/2011	WO2011130616A1 Pyrrolobenzodiazepines used to treat proliferative diseases
10/20/2011	WO2011130613A1 Targeted pyrrolobenzodiazapine conjugates
10/20/2011	WO2011130611A2 Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity
10/20/2011	WO2011130603A2 Anti-vla-4 antibodies
10/20/2011	WO2011130598A1 Pyrrolobenzodiazepines and conjugates thereof
10/20/2011	WO2011130566A2 Method for treating solid tumors
10/20/2011	WO2011130486A2 Combination treatments and formulations for cancer
10/20/2011	WO2011130481A1 Pyrrolopyrazinone inhibitors of kinases
10/20/2011	WO2011130478A1 Phthalazin-(2h)-one inhibitors of kinases
10/20/2011	WO2011130476A2 Polymer-based therapeutic agents
10/20/2011	WO2011130429A2 Methods and materials for treating lung cancer
10/20/2011	WO2011130425A1 Method to detect endothelial cell massive calcium accumulation death
10/20/2011	WO2011130317A2 Therapeutic agents having reduced toxicity
10/20/2011	WO2011130249A2 Methods and compositions for inhibition of treg cells
10/20/2011	WO2011130232A1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
10/20/2011	WO2011130164A2 Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
10/20/2011	WO2011129936A2 Compositions and methods for the prevention and treatment of cancer
10/20/2011	WO2011129680A1 A use of an effective amount of a composition comprising o. stamineus leaf extract
10/20/2011	WO2011129549A2 Anticancer drug delivery system using ph-sensitive metal nanoparticles
10/20/2011	WO2011129494A1 Nucleolin specific aptamer and use thereof
10/20/2011	WO2011129427A1 Diagnostic agent and therapeutic agent for cancer
10/20/2011	WO2011129379A1 Novel anti-hsp90 monoclonal antibody
10/20/2011	WO2011129371A1 GENE GROUP CAPABLE OF ENHANCING ANTI-TUMOR EFFECT OF 5-FU ALONE OR IFN-α/5-FU COMBINATION
10/20/2011	WO2011129365A1 Antitumor agent
10/20/2011	WO2011129348A1 Composition for treatment of cancer which is produced from cancer-tissue-derived cell mass or cancer cell aggregate, and process for production of immunotherapeutic agent and method for evaluation of efficacy of immunotherapy both using the composition
10/20/2011	WO2011128905A1 Novel nutraceutical formulation isolated from the plants of family scrophulariaceae as anticancer, antiviral, antiaging and immunostimulating agent
10/20/2011	WO2011128436A1 Combination of hypoxia-inducible factor-1 inhibitors and toll-like receptor-3 agonists for treating solid tumors
10/20/2011	WO2011128434A2 Treatment of endocrine resistant breast cancer
10/20/2011	WO2011128405A1 Combination of organic compounds
10/20/2011	WO2011128403A1 Organic compound for use in the treatment of liver cancer
10/20/2011	WO2011128388A2 Oxazole and thiazole compounds as ksp inhibitors
10/20/2011	WO2011128381A1 Triazole compounds as ksp inhibitors
10/20/2011	WO2011128245A1 Homeopathic medicament comprising phenacetin for the treatment of cancer
10/20/2011	WO2011127567A1 Inhibitors of protein tyrosine kinase activity
10/20/2011	WO2011127537A1 Radiation sensitiser compositions
10/20/2011	WO2011127532A1 Tethered matrix metalloproteinase inhibitor
10/20/2011	WO2011127519A1 Combination treatment with vegf-c antagonists
10/20/2011	WO2011084685A3 Saposin-a derived peptides and uses thereof
10/20/2011	WO2011084523A3 Ulk1 compositions, inhibitors, screening and methods of use
10/20/2011	WO2011083088A3 Methods for treating colorectal cancer
10/20/2011	WO2011082273A3 Substituted pyrrolo-aminopyrimidine compounds
10/20/2011	WO2011082268A3 Substituted naphthalenyl-pyrimidine compounds
10/20/2011	WO2011079230A3 Heterocyclic compounds as janus kinase inhibitors
10/20/2011	WO2011072218A3 Stable formulations for lyophilizing therapeutic particles
10/20/2011	WO2011072181A3 Method of treating pancreatic cancer
10/20/2011	WO2011066542A3 6-substituted estradiol derivatives and methods of use
10/20/2011	WO2011066521A3 Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
10/20/2011	WO2011066417A3 Antibodies and conjugates for modulators of angiogenesis
10/20/2011	WO2011066374A3 Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
10/20/2011	WO2011066371A3 Antibodies to il-6 and use thereof
10/20/2011	WO2011060049A3 Spiro-oxindole mdm2 antagonists
10/20/2011	WO2011052923A3 Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
10/20/2011	WO2011047173A9 Pharmaceutical compositions for oral administration
10/20/2011	US20110258713 Compositions and methods for re-programming cells without genetic modification
10/20/2011	US20110257601 Vegf antagonist formulations for intravitreal administration
10/20/2011	US20110257586 Calciumphosphate-based nanoparticles as carrier-systems for photodynamic therapy
10/20/2011	US20110257583 Thiadiazole Compounds and Uses Thereof

1 ... 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 ... 2211